Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Neil P. Shah(Unknown), Kristina M. Gregory(National Comprehensive Cancer Network), Vivian G. Oehler(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ravi Bhatia(University of Alabama at Birmingham), Moshe Talpaz(University of Michigan), Tiffany Tanaka(UC San Diego Health System), B. Douglas Smith(Johns Hopkins University), Michael W. Drazer(Susan Thompson Buffett Foundation), Jessica K. Altman(Northwestern University), Leland Metheny(Cancer Institute (WIA)), Iskra Pusic(Washington University in St. Louis), Maria L. Amaya(University of Colorado Denver), Srinivas K. Tantravahi(University of Utah), Keith W. Pratz(University of Pennsylvania), James E. Thompson(Roswell Park Comprehensive Cancer Center), Lori J. Maness(Susan Thompson Buffett Foundation), Jennifer E. Vaughn(The Ohio State University), Michael Styler(Fox Chase Cancer Center), Peter Curtin(City Of Hope National Medical Center), Onyee Chan(Moffitt Cancer Center), Kebede H. Begna(Mayo Clinic), William Shomali(Stanford Medicine), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Hema Sundar(National Comprehensive Cancer Network), David T. Yang(University of Wisconsin–Madison), Robert H. Collins(Texas Oncology), Steven Tsai(University of Colorado Cancer Center), Joan Clements(Nierstichting), Joseph O. Moore(Cancer Institute (WIA)), Jeanna Welborn(UC Davis Comprehensive Cancer Center), Michal G. Rose(Yale Cancer Center), Sanjay Mohan(Breast Cancer Research Foundation), Ellin Berman(Memorial Sloan Kettering Cancer Center)
Cited by 116
Related Papers
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k